Syndax Pharmaceuticals Investor Relations Material
Latest events
FDA Announcement
Syndax Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Syndax Pharmaceuticals Inc
Access all reports
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops therapies for the treatment of cancer. The Company is engaged in the development and commercialization of novel medicines for cancer. The Company's pipeline includes BTG4-L1, a small molecule that has shown preclinical activity in treating multiple tumor types including breast, ovarian, prostate and central nervous system cancers; and SID418, which has demonstrated remarkable antiviral activity against Ebola virus and related filoviruses. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Key slides for Syndax Pharmaceuticals Inc
Corporate Presentation
Syndax Pharmaceuticals Inc
Q2 2024
Syndax Pharmaceuticals Inc
Latest articles
Cristiano Amon: Qualcomm's 5G Specialist CEO
Cristiano Amon, Qualcomm CEO, has spent two decades at the company while taking on several roles, developing both technical and business expertise.
16 Sep 2024
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Ticker symbol
SNDX
Country
🇺🇸 United States